Onchilles raises $25M to take cancer-killing enzyme into human studiesnews2025-11-07T12:00:14+00:00November 7th, 2025|Endpoints News|
#ASN25: Eledon plots path forward for kidney transplant drug despite Phase 2 missnews2025-11-06T23:30:09+00:00November 6th, 2025|Endpoints News|
#ASN25: Vera outlines full Phase 3 win for kidney drug, preps for FDA filing by year’s endnews2025-11-06T15:11:58+00:00November 6th, 2025|Endpoints News|
J&J’s Caplyta approved by FDA as add-on treatment for depressionnews2025-11-06T14:20:11+00:00November 6th, 2025|Endpoints News|
Low vaccine uptake hampers Moderna earnings, including meager RSV salesnews2025-11-06T12:00:52+00:00November 6th, 2025|Endpoints News|
Lilly’s amylin moves to Phase 3 after success in next obesity drug wavenews2025-11-06T11:45:50+00:00November 6th, 2025|Endpoints News|
Centessa says early data for narcolepsy drug support registrational plansnews2025-11-05T12:00:41+00:00November 5th, 2025|Endpoints News|
Arena BioWorks shuts down after investors pull plug on bid to reinvent biotechnews2025-11-04T23:25:15+00:00November 4th, 2025|Endpoints News|
Pfizer trims pipeline, reports 7% revenue decline for Q3news2025-11-04T12:07:42+00:00November 4th, 2025|Endpoints News|
Compass plots quicker path to approval, launch readiness for depression drugnews2025-11-04T11:46:13+00:00November 4th, 2025|Endpoints News|
